255 related articles for article (PubMed ID: 22237311)
1. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.
Bettica P; Squassante L; Groeger JA; Gennery B; Winsky-Sommerer R; Dijk DJ
Neuropsychopharmacology; 2012 Apr; 37(5):1224-33. PubMed ID: 22237311
[TBL] [Abstract][Full Text] [Related]
2. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.
Bettica P; Squassante L; Zamuner S; Nucci G; Danker-Hopfe H; Ratti E
Sleep; 2012 Aug; 35(8):1097-104. PubMed ID: 22851805
[TBL] [Abstract][Full Text] [Related]
3. The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia.
Walsh JK; Deacon S; Dijk DJ; Lundahl J
Sleep; 2007 May; 30(5):593-602. PubMed ID: 17552374
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled sleep laboratory studies on the acute effects of zolpidem on objective and subjective sleep and awakening quality in nonorganic insomnia related to neurotic and stress-related disorder.
Saletu-Zyhlarz G; Anderer P; Brandstätter N; Dantendorfer K; Gruber G; Mandl M; Ritter K; Zoghlami A; Saletu B
Neuropsychobiology; 2000; 41(3):139-48. PubMed ID: 10754428
[TBL] [Abstract][Full Text] [Related]
5. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
[TBL] [Abstract][Full Text] [Related]
6. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.
Bettica P; Nucci G; Pyke C; Squassante L; Zamuner S; Ratti E; Gomeni R; Alexander R
J Psychopharmacol; 2012 Aug; 26(8):1058-70. PubMed ID: 21730017
[TBL] [Abstract][Full Text] [Related]
7. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
8. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.
Sun H; Kennedy WP; Wilbraham D; Lewis N; Calder N; Li X; Ma J; Yee KL; Ermlich S; Mangin E; Lines C; Rosen L; Chodakewitz J; Murphy GM
Sleep; 2013 Feb; 36(2):259-67. PubMed ID: 23372274
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
[TBL] [Abstract][Full Text] [Related]
10. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.
Steiner MA; Lecourt H; Strasser DS; Brisbare-Roch C; Jenck F
Neuropsychopharmacology; 2011 Mar; 36(4):848-56. PubMed ID: 21150905
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
[TBL] [Abstract][Full Text] [Related]
14. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.
Hoever P; Dorffner G; Beneš H; Penzel T; Danker-Hopfe H; Barbanoj MJ; Pillar G; Saletu B; Polo O; Kunz D; Zeitlhofer J; Berg S; Partinen M; Bassetti CL; Högl B; Ebrahim IO; Holsboer-Trachsler E; Bengtsson H; Peker Y; Hemmeter UM; Chiossi E; Hajak G; Dingemanse J
Clin Pharmacol Ther; 2012 Jun; 91(6):975-85. PubMed ID: 22549286
[TBL] [Abstract][Full Text] [Related]
15. Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia.
Monti JM; Alvariño F; Monti D
Sleep; 2000 Dec; 23(8):1075-84. PubMed ID: 11145322
[TBL] [Abstract][Full Text] [Related]
16. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation.
Herrmann WM; Kubicki ST; Boden S; Eich FX; Attali P; Coquelin JP
J Int Med Res; 1993; 21(6):306-22. PubMed ID: 8143886
[TBL] [Abstract][Full Text] [Related]
17. Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia.
Lundahl J; Staner L; Staner C; Loft H; Deacon S
Psychopharmacology (Berl); 2007 Nov; 195(1):139-46. PubMed ID: 17653697
[TBL] [Abstract][Full Text] [Related]
18. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.
Hoever P; de Haas S; Winkler J; Schoemaker RC; Chiossi E; van Gerven J; Dingemanse J
Clin Pharmacol Ther; 2010 May; 87(5):593-600. PubMed ID: 20376002
[TBL] [Abstract][Full Text] [Related]
19. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo.
Roth T; Roehrs T; Vogel G
Sleep; 1995 May; 18(4):246-51. PubMed ID: 7618022
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
